Researchers at Brown University have created a brain-computer interface (BCI) with 200 electrodes providing 48 megabits per second (Mbit/s) of neural signalsThe trial participants – a 35-year-old man and a 63-year-old man, paralysed by spinal cord injuries – were able to use the BrainGate system in their homes, not a lab setting . Unencumbered by cables, they used the BCI continuously for up to 24 hours, giving researchers long-duration data, including while the participants slept.Brown University has an agreement with neural engineering and neuroprosthetics company Blackrock Microsystems, to make the device available for researchers around the world.https://www.futuretimeline.net/blog/2021/04/2-first-high-bandwidth-wireles
Queensland-based AnteoTech has received European accreditation for its 15-minute COVID-19 rapid test, to take the fight on the illness overseas. Their innovative, point-of-care COVID-19 antigen rapid test platform, EuGeni now has Conformitè Europëenne Mark registration, meaning it meets the health and safety rules in both the UK and Europe. The company will now start to commercialise their product in Australia, with the test based on their proprietary binding technology paired with global advancements in assay detection systems. The next step is gaining approval from the TGA in Australia to start the manufacturing process. | https://www.anteotech.com/announcements/test-platform-and-covid-19-test-receive-ce-mark-approval/
Researchers at the University of Colorado Cancer Centre have published their work on NLRP3 - an intracellular complex found to participate in melanoma-mediated inflammation leading to tumour growth and progression. The researchers found that by inhibiting this complex, they can reduce inflammation and tumour growth. The studies have so far used an oral NLRP3 inhibitor (Dapansutrile) which has shown to be effective in treating gout and heart disease. It is currently being tested in COVID-19. | https://medicalxpress.com/news/2021-04-drug-tumors.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
